Gemcitabine-resistant pancreatic cancer cells have been reported to exhibit high activation of p-FAK (Tyr397), and inhibitory RNAi treatment increases gemcitabine-induced cytotoxicity [79]. The gene discussed is PTK2; the disease is pancreatic neoplasm.